Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia [Seeking Alpha]
Applied Therapeutics, Inc. (APLT)
Last applied therapeutics, inc. earnings: 11/13 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Govorestat (AT-007) is in late-stage regulatory approval for galactosemia, with a PDUFA date set for November 2024. APLT holds $146.5 million in cash, ensuring a sufficient runway to FDA approval and initial product revenues by early 2025. The Company has a diversified pipeline, including AT-007 for SORD Deficiency and PMM2-CDG and AT-001 for diabetic cardiomyopathy and peripheral neuropathy. I think APLT's valuation seems reasonable given its progress and financials, so I rate it a "strong-buy" despite biotech risks. Applied Therapeutics, Inc. ( NASDAQ: APLT ) is a promising clinical-stage biotech that focuses on treating symptoms of galactosemia in the central nervous system [CNS]. Galactosemia is rare when the body lacks a particular enzyme that metabolizes galactose. As Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
APLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APLT alerts
High impacting Applied Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
APLT
News
- Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA [Yahoo! Finance]Yahoo! Finance
- Applied Therapeutics, Inc. (NASDAQ: APLT) had its price target raised by analysts at Citigroup Inc. from $8.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer [Seeking Alpha]Seeking Alpha
APLT
Earnings
- 8/7/24 - Miss
APLT
Sec Filings
- 8/23/24 - Form 4
- 8/23/24 - Form 4
- 8/14/24 - Form 4
- APLT's page on the SEC website